Mido Bio

MITRO, established in 2012 and headquartered in Jiangning District, Nanjing City, operates in the radiopharmaceutical industry, providing Contract Research, Development, and Manufacturing Organization (CRDMO) services. With offices in China, the United States, and the United Kingdom, and a workforce of over 200 employees, MITRO serves global pharmaceutical and biomedical clients. The company focuses on radioisotope labeled molecular imaging, facilitating the development of innovative drugs. MITRO's business model includes offering preclinical and clinical studies, R&D services, and imaging services. The company generates revenue through service contracts with over 700 global sponsors and has achieved 20 clinical approvals.

Keywords: Radiopharmaceutical, CRDMO, molecular imaging, innovative drugs, preclinical studies, clinical studies, R&D services, imaging services, global sponsors, drug development.